Citius Pharmaceuticals, Inc. (modificare)
Versiunea de la data 25 noiembrie 2024 05:16
, Luni, la 05:16The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Citius Pharmaceuticals, Inc. listata cu simbolul US.CTXR ==Descriere companie== Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies. | Citius Pharmaceuticals Inc. (www.citiuspharma.com) is a specialty pharmaceutical company. The Company is focused on development of critical care products, such as anti-infective products in adjunct cancer care, prescription products and stem cell therapy. The Company has three products: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CITI-002 helps to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap product (CITI-101) is a malleable, [[BIO|bio]]-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||